1/27
08:00 am
arqt
Arcutis to Present at the Guggenheim SMID Cap Biotech Conference
Medium
Report
Arcutis to Present at the Guggenheim SMID Cap Biotech Conference
1/13
08:04 am
arqt
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.
Medium
Report
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.
1/12
08:30 am
arqt
Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million
Medium
Report
Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million
1/7
11:18 am
arqt
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its price target raised by analysts at Mizuho from $19.00 to $20.00. They now have an "outperform" rating on the stock.
Low
Report
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its price target raised by analysts at Mizuho from $19.00 to $20.00. They now have an "outperform" rating on the stock.
1/6
04:00 pm
arqt
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/30
07:37 am
arqt
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $19.00 price target on the stock.
Low
Report
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $19.00 price target on the stock.
12/26
12:03 pm
arqt
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024 [Yahoo! Finance]
Low
Report
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024 [Yahoo! Finance]
12/16
08:07 am
arqt
Arcutis Submits ZORYVE® (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis [Yahoo! Finance]
Medium
Report
Arcutis Submits ZORYVE® (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis [Yahoo! Finance]
12/16
08:00 am
arqt
Arcutis Submits ZORYVE® (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
Medium
Report
Arcutis Submits ZORYVE® (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
12/6
04:03 pm
arqt
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
12/6
04:00 pm
arqt
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/3
08:13 am
arqt
Arcutis Announces Promotions on Executive Management Team [Yahoo! Finance]
Low
Report
Arcutis Announces Promotions on Executive Management Team [Yahoo! Finance]
12/3
08:00 am
arqt
Arcutis Announces Promotions on Executive Management Team
Low
Report
Arcutis Announces Promotions on Executive Management Team
11/27
11:17 am
arqt
Arcutis Biotherapeutics, Inc. (ARQT) Now Trades Above Golden Cross: Time to Buy? [Yahoo! Finance]
Low
Report
Arcutis Biotherapeutics, Inc. (ARQT) Now Trades Above Golden Cross: Time to Buy? [Yahoo! Finance]
11/20
11:12 am
arqt
Arcutis Biotherapeutics, Inc. (ARQT) Crossed Above the 50-Day Moving Average: What That Means for Investors [Yahoo! Finance]
Low
Report
Arcutis Biotherapeutics, Inc. (ARQT) Crossed Above the 50-Day Moving Average: What That Means for Investors [Yahoo! Finance]
11/20
11:12 am
arqt
Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 200-Day Moving Average [Yahoo! Finance]
Low
Report
Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 200-Day Moving Average [Yahoo! Finance]
11/19
10:51 am
arqt
Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average [Yahoo! Finance]
Medium
Report
Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average [Yahoo! Finance]
11/19
08:20 am
arqt
Frazier Life Sciences Appoints John Smither and Jim Williams as Senior Advisors [Yahoo! Finance]
Medium
Report
Frazier Life Sciences Appoints John Smither and Jim Williams as Senior Advisors [Yahoo! Finance]
11/13
08:00 am
arqt
Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour
Low
Report
Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour
11/7
08:36 am
arqt
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $18.00 price target on the stock.
Medium
Report
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $18.00 price target on the stock.
11/7
02:31 am
arqt
Arcutis Biotherapeutics Inc (ARQT) Q3 2024 Earnings Call Highlights: Robust Growth and ... [Yahoo! Finance]
Medium
Report
Arcutis Biotherapeutics Inc (ARQT) Q3 2024 Earnings Call Highlights: Robust Growth and ... [Yahoo! Finance]
11/7
02:26 am
arqt
Arcutis Biotherapeutics, Inc. (ARQT) Q3 2024 Earnings Call Transcript [Seeking Alpha]
Medium
Report
Arcutis Biotherapeutics, Inc. (ARQT) Q3 2024 Earnings Call Transcript [Seeking Alpha]
11/6
04:00 pm
arqt
Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update
Medium
Report
Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update
11/5
08:04 am
arqt
Earnings To Watch: Arcutis Biotherapeutics Inc (ARQT) Reports Q3 2024 Result [Yahoo! Finance]
Medium
Report
Earnings To Watch: Arcutis Biotherapeutics Inc (ARQT) Reports Q3 2024 Result [Yahoo! Finance]
11/4
04:00 pm
arqt
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)